
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Income Statement | ||||||
Revenue | $44.2M | $48.2M | $61M | $12.6M | $16.8M | |
Gross Profit | $11.9M | $13.6M | $18.3M | $2.8M | $5.1M | |
Operating Income | $4.3M | $6.3M | $10.3M | $777K | $2.7M | |
EBITDA | $9.6M | $5.6M | $10.6M | $1M | $3.1M | |
Diluted EPS | $1.58 | $0.84 | $2.00 | $0.14 | $0.61 |
Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $22.7M | $26.1M | $31.4M | $36.6M | $44.3M | |
Total Assets | $38.4M | $42.1M | $47.6M | $51.4M | $60.4M | |
Current Liabilities | $4.9M | $6M | $11.7M | $10M | $17.1M | |
Total Liabilities | $16.5M | $20.1M | $23.1M | $19.6M | $28.6M | |
Total Equity | $21.8M | $22M | $24.5M | $31.8M | $31.8M | |
Total Debt | $8.9M | $12.2M | $12.7M | $12.1M | $16.4M |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -$2.6M | $4.1M | $2.8M | $710K | -$4.2M | |
Cash From Investing | -$403K | -$2.3M | -$1.2M | -$1.9M | -$542K | |
Cash From Financing | -$1.9M | -$864K | -$2.9M | $558K | $1.7M | |
Free Cash Flow | -$3.8M | $3M | $1.6M | $77K | -$4.7M |
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
In the current month, PDEX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PDEX average analyst price target in the past 3 months is $54.00.
According to analysts, the consensus estimate is that Pro-Dex share price will rise to $54.00 per share over the next 12 months.
Analysts are divided on their view about Pro-Dex share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pro-Dex is a Sell and believe this share price will drop from its current level to $54.00.
The price target for Pro-Dex over the next 1-year time period is forecast to be $54.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Pro-Dex is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
You can purchase shares of Pro-Dex via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pro-Dex shares.
Pro-Dex was last trading at $47.11 per share. This represents the most recent stock quote for Pro-Dex. Yesterday, Pro-Dex closed at $40.08 per share.
In order to purchase Pro-Dex stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
For many years, Walmart (NYSE:WMT) has been the world’s largest…
The AI race has heated up significantly but returns on…
Market Cap: $3.3T
P/E Ratio: 36x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.6T
P/E Ratio: 36x
Willdan Group [WLDN] is down 3.97% over the past day.
Guardant Health [GH] is up 8.39% over the past day.
Pro-Dex [PDEX] is up 17.54% over the past day.